Delving into the Latest Updates on PT Dexa Medica with Synapse

Overview

Tags

Nervous System Diseases

Digestive System Disorders

Endocrinology and Metabolic Disease

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Endocrinology and Metabolic Disease	1
Neoplasms	1

Top 5 Drug Type	Count

Herbal medicine	4
Small molecule drug	2

Top 5 Target	Count

ATPase	1
Fibrinogen	1

This is a randomized, double-blind and placebo-controlled study involving mothers and their babies evaluating the effect of a 15-day-supplementation with a product containing extracts derived from a combination of herbal plants (katuk & torbangun leaves) and snakehead fish in stimulating breast milk production.

Start Date01 Aug 2024

Sponsor / Collaborator

PT Dexa Medica

100 Clinical Results associated with PT Dexa Medica

Login to view more data

0 Patents (Medical) associated with PT Dexa Medica

Login to view more data

10

Literatures (Medical) associated with PT Dexa Medica

31 Dec 2024·CyTA - Journal of Food

Unveiling the importance role of lutein-plant-based nanoencapsulation – a future effort to improve their stability and bioaccessibility in combating ocular melanoma

Author: Syahputra, Rony Abdi ; Nurkolis, Fahrul ; Syauki, Andi Yasmin ; Subali, Dionysius ; Kumalawati, Dian Aruni ; Astuti Taslim, Nurpudji ; Hardinsyah, Hardinsyah ; Tjandrawinata, Raymond R. ; Qhabibi, Faqrizal Ria ; Surya, Reggie ; Kim, Bonglee ; Iqhrammullah, Muhammad ; Permatasari, Happy Kurnia ; Anggari, Vika ; Mayulu, Nelly ; Kurniawan, Rudy

A review.Despite its potential benefits, lutein availability can be limited due to inadequate dietary intake of fruits, vegetables, and seaweed.Addnl., lutein faces challenges related to gastrointestinal absorption due to its physicochem. characteristics.To tackle these issues, fortifying staple foods with lutein is proposed, but its low solubility and susceptibility to oxidative degradation present hurdles.Nanoencapsulation technol. emerges as a promising solution for improving lutein stability during food processing, storage, and absorption.However, lutein's stability remains a challenge, with susceptibility to degradation by temperature, UV-light, and oxygen exposure.Food processing involving high temperatures can cause degradation, while specific UV-wavelengths lead to cleavage of lutein mols.This critical viewpoint carries substantial scientific significance by urging researchers globally to prioritize clin. investigations and the advancement of plant-based lutein nanoencapsulation in basic dietary items.Clin. studies focusing on lutein-plant-based nanoencapsulation approaches are essential to improve its stability and bioaccessibility, ultimately contributing to better vision health.

07 Apr 2021·Stroke Research and Treatment

Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial

Article

Author: Tjandrawinata, Raymond R. ; Pinzon, Rizaldy Taslim ; Veronica, Vanessa ; Wijaya, Vincent Ongko

Background. There are still some unmet needs for stroke management and safety. DLBS1033 is a protein fraction extracted from the earthworm Lumbricus rubellus that has shown fibrinolytic and fibrinogenolytic activities, reduces blood viscosity, and inhibits platelet aggregation that it can be considered an add-on therapy and potential medical breakthrough in acute ischemic stroke management. Objective. This study is aimed at measuring the benefit of DLBS1033 in acute ischemic stroke management. Methods. This was a randomized, open-label trial at a referral stroke center from November 2019 to December 2020. Subjects who met the inclusion criteria were randomly divided into a control group and an experimental group. The control group received standard therapy consisting of aspirin 100 mg once daily, atorvastatin 20 mg once daily, and vitamin B12 100 mg three times daily. The experimental group received standard therapy and DLBS1033 three times daily. The functional outcomes were measured using the National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS) at baseline, hospital discharge, and day 30. Results. Collected data from 180 subjects was analyzed. The NIHSS scores’ improvements were significantly greater in the experimental group compared to the control group at both hospital discharge (−5.57±2.16vs.−3.64±2.65;p<0.001) and day 30 (−6.62±2.64vs.−5.14±2.41;p=0.001). Compared with the control group, the improvements in the BI scores were significantly better in the experimental group, at both hospital discharge (10.69±5.36vs.6.64±5.04;p<0.001) and day 30 (10.9±8.19vs.8.56±7.45;p=0.003). The distribution of mRS scores was improved in both groups during 30 days of follow-up and was more favorable in the experimental group. In both groups, a favorable outcome (mRS<2) was achieved better at day 30 (86.7% vs. 80%;p=0.302) than at baseline (0% vs. 6.7%;p=0.028) and at hospital discharge (58.9% vs. 43.3%;p=0.085). There was no clinically significant adverse event related to the study product. Conclusions. DLBS1033 in addition to the standard care was more effective in improving functional status compared to standard care alone in acute ischemic stroke patients with a similar safety profile.

01 Mar 2017·Journal of Herbal Medicine

Development of orodispersible films with selected Indonesian medicinal plant extracts

Author: J. Carolina Visser ; Christina Avanti ; Gabriela Eugresya ; Henderik W. Frijlink ; Raymond R. Tjandrawinata ; Wouter L.J. Hinrichs ; Herman J. Woerdenbag

This study focused on the incorporation into orodispersible films (ODFs) of the dried extracts of five selected Indonesian medicinal plants: Lagerstroemia speciosa (L.) Pers. (LS), Phyllanthus niruri L. (PN), Cinnamomum burmanii Blume (CB), Zingiber officinale Roscoe (ZO) and Phaleria macrocarpa (Scheff.) Boerl (PM). Suitable formulae for solvent casting were developed to produce extract containing films with either a combination of hypromellose (HPMC) with carbomer 974P or only hydroxypropyl cellulose (HPC) as film forming agent. Each extract and dose in a formulation rendered different ODF characteristics. Extracts of ZO and CB and a low dose of PM extract (5 mg) could be formulated into an ODF containing HPMC with carbomer 974P. For extracts of LS, PN and high doses of PM extract HPC were the most suitable film forming agents. For each extract a different maximum load in a film was found, up to maximum 30 mg for extracts of LS and PN. Good products were obtained with 5 mg and 10 mg of each extract. The quality of the produced ODFs was tested organoleptically, and characterized by determination of uniformity of weight, thickness, disintegration time, surface pH, crystallinity, mechanical properties, water content, residual ethanol, dynamic vapour sorption, physical stability and control of the qualitative profiling of extract composition in the film. Thin layer chromatography indicated that all five extracts remained chemically unaffected during ODF production. In conclusion, ODFs are a suitable novel dosage form for herbal extracts, provided that tailor-made formulations are developed for each extract and each dose.

100 Deals associated with PT Dexa Medica

Login to view more data

100 Translational Medicine associated with PT Dexa Medica

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Phase 3 Clinical

Approved

4

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DLBS-3233	Diabetes Mellitus, Type 2 More	Approved
Phaleria macrocarpa extract	Breast Cancer More	Approved
DLBS-1442	Dysmenorrhea More	Approved
Lumbricus rubellus extract ( Fibrinogen )	Thrombosis More	Approved
DLBS-2411 ( ATPase )	Dyspepsia More	Phase 3